On May 6, 2020, Predictive Oncology announced the acquisition of Soluble Therapeutics and partnership and licensing of a novel nanoparticle vaccine platform for development of a COVID-19 vaccine. Thevaccine technology being developed by Dr. Daniel Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein) which follows a foundational vaccine platform developed earlier using another self-assembling protein called ferritin , an iron storage protein found in all living things.

The ferritin platform is currently exploited by NIH in its exploration of the universal flu vaccine which completed phase I clinical trials earlier this year and is currently recruiting for a second Phase 1 trial on a modified version of the ferritin self-assembly universal vaccine.